This 16 minute video tells the story of one of this century's most extraordinary scientific discoveries - induced pluripotent stem cells, or iPS cells. Medical doctor and scientist Shinya Yamanaka describes his Nobel prize-winning work. Together with other leading stem cell researchers, he talks about the scientific, medical and ethical implications of his reprogramming experiments. Cameron Duguid's distinctive animations take us inside the reprogrammed cell, and bring the science to life on screen.
Find out about the next revolution in medicine and how it can change your life.
Tune in to find out about the next revolution in medicine and how it can change your life. Featuring Curt Civin, Director of the Center for Stem Cell Biology and Regenerative Medicine. Assistant Dean for Research University of Maryland School of Medicine.
There is considerable excitement about the use of stem cells for cardiovascular disease. Stem cells are unspecialized cells with the unique property to self-renew or make copies of themselves and to differentiate into specialized cells. The goal of stem cell therapy is to enhance the body's natural process of regeneration. There are a considerable number of stem cells currently under investigation for patients with heart attacks, angina, heart failure, and peripheral arterial disease. We have made considerable progress but have many questions left to answer.
Timothy Henry, MD, FACC, is Chief of Cardiology at Cedars Sinai Heart Institute in Los Angeles, California. Dr. Henry earned his bachelor's degree at the University of North Dakota, graduated from medical school at University of California, San Francisco, in 1982, and was chief medicine resident from 1982--1986 at University of Colorado Health Sciences Center. He completed his training as a cardiology fellow, chief cardiology fellow, and interventional cardiology fellow at University of Minnesota in 1991. His research interests include interventional cardiology, acute myocardial infarction and novel therapies, including stem cell and gene therapy, for patients who are not candidates for standard revascularization techniques.